Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 7659462, 6 pages
https://doi.org/10.1155/2017/7659462
Research Article

CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells

1Biology Discipline, University of Minnesota, Morris, MN, USA
2Department of Immunology, Mayo Clinic, Rochester, MN, USA

Correspondence should be addressed to Rachel M. Gibbons Johnson; ude.nmu.sirrom@snhojmr

Received 7 August 2017; Revised 13 September 2017; Accepted 24 September 2017; Published 18 October 2017

Academic Editor: Guobing Chen

Copyright © 2017 Meagan R. Rollins and Rachel M. Gibbons Johnson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Dong and L. Chen, “B7-H1 pathway and its role in the evasion of tumor immunity,” Journal of Molecular Medicine, vol. 81, no. 5, pp. 281–287, 2003. View at Publisher · View at Google Scholar
  2. J. M. Chemnitz, R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley, “SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation,” The Journal of Immunology, vol. 173, no. 2, pp. 945–954, 2004. View at Publisher · View at Google Scholar
  3. R. V. Parry, J. M. Chemnitz, K. A. Frauwirth et al., “CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms,” Molecular and Cellular Biology, vol. 25, no. 21, pp. 9543–9553, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Brahmer, C. G. Drake, I. Wollner et al., “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates,” Journal of Clinical Oncology, vol. 28, no. 19, pp. 3167–3175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. O. Hamid, C. Robert, A. Daud et al., “Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 134–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ribas, I. Puzanov, R. Dummer et al., “Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial,” The Lancet Oncology, vol. 16, no. 8, pp. 908–918, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Robert, G. V. Long, B. Brady et al., “Nivolumab in previously untreated melanoma without BRAF mutation,” The New England Journal of Medicine, vol. 372, no. 4, pp. 320–330, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Motzer, B. Escudier, D. F. McDermott et al., “Nivolumab versus everolimus in advanced renal-cell carcinoma,” The New England Journal of Medicine, vol. 373, no. 19, pp. 1803–1813, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Robert, J. Schachter, G. V. Long et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 372, no. 26, pp. 2521–2532, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. E. B. Garon, N. A. Rizvi, R. Hui et al., “Pembrolizumab for the treatment of non–small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 21, pp. 2018–2028, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Larkin, V. Chiarion-Sileni, R. Gonzalez et al., “Combined nivolumab and ipilimumab or monotherapy in untreated melanoma,” The New England Journal of Medicine, vol. 373, no. 1, pp. 23–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Borghaei, L. Paz-Ares, L. Horn et al., “Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer,” The New England Journal of Medicine, vol. 373, no. 17, pp. 1627–1639, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Brahmer, K. L. Reckamp, P. Baas et al., “Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer,” The New England Journal of Medicine, vol. 373, no. 2, pp. 123–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Larkin, D. Minor, S. D'Angelo et al., “Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial,” Journal of Clinical Oncology, 2017. View at Publisher · View at Google Scholar
  15. S. Antonia, S. B. Goldberg, A. Balmanoukian et al., “Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study,” The Lancet Oncology, vol. 17, no. 3, pp. 299–308, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. J. E. Rosenberg, J. Hoffman-Censits, T. Powles et al., “Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial,” The Lancet, vol. 387, no. 10031, pp. 1909–1920, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. H. L. Kaufman, J. Russell, O. Hamid et al., “Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial,” Lancet Oncology, vol. 17, no. 10, pp. 1374–1385, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Rittmeyer, F. Barlesi, D. Waterkamp et al., “Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial,” The Lancet, vol. 389, no. 10066, pp. 255–265, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman, “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses,” Immunity, vol. 27, no. 1, pp. 111–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. J. Butte, V. Peña-Cruz, M.-J. Kim, G. J. Freeman, and A. H. Sharpe, “Interaction of human PD-L1 and B7-1,” Molecular Immunology, vol. 45, no. 13, pp. 3567–3572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Park, R. Omiya, Y. Matsumura et al., “B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance,” Blood, vol. 116, no. 8, pp. 1291–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Yang, L. V. Riella, S. Chock et al., “The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo,” The Journal of Immunology, vol. 187, no. 3, pp. 1113–1119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. M. Paterson, K. E. Brown, M. E. Keir et al., “The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo,” The Journal of Immunology, vol. 187, no. 3, pp. 1097–1105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Pellegrini, G. Belz, P. Bouillet, and A. Strasser, “Shutdown of an acute T cell immune response to viral infection is mediated by the proapoptotic Bcl-2 homology 3-only protein Bim,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 24, pp. 14175–14180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Wojciechowski, P. Tripathi, T. Bourdeau et al., “Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis,” Journal of Experimental Medicine, vol. 204, no. 7, pp. 1665–1675, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Prlic and M. J. Bevan, “Exploring regulatory mechanisms of CD8+ T cell contraction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 43, pp. 16689–16694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. R. M. Gibbons, X. Liu, V. Pulko et al., “B7-H1 limits the entry of effector CD8+ T cells to the memory pool by upregulating Bim,” Oncoimmunology, vol. 1, no. 7, pp. 1061–1073, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. C.-H. Chang, J. Qiu, D. O’Sullivan et al., “Metabolic competition in the tumor microenvironment is a driver of cancer progression,” Cell, vol. 162, no. 6, pp. 1229–1241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Patsoukis, K. Bardhan, P. Chatterjee et al., “PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation,” Nature Communications, vol. 6, article 6692, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. X.-J. Qi, G. M. Wildey, and P. H. Howe, “Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function,” Journal of Biological Chemistry, vol. 281, no. 2, pp. 813–823, 2006. View at Publisher · View at Google Scholar · View at Scopus